DE69100282D1 - Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. - Google Patents

Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.

Info

Publication number
DE69100282D1
DE69100282D1 DE9191904163T DE69100282T DE69100282D1 DE 69100282 D1 DE69100282 D1 DE 69100282D1 DE 9191904163 T DE9191904163 T DE 9191904163T DE 69100282 T DE69100282 T DE 69100282T DE 69100282 D1 DE69100282 D1 DE 69100282D1
Authority
DE
Germany
Prior art keywords
insulin
hypertension
treatment
active substances
sensitizing active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE9191904163T
Other languages
English (en)
Other versions
DE69100282T3 (de
DE69100282T2 (de
Inventor
Jerry Colca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23898474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69100282(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of DE69100282D1 publication Critical patent/DE69100282D1/de
Application granted granted Critical
Publication of DE69100282T2 publication Critical patent/DE69100282T2/de
Publication of DE69100282T3 publication Critical patent/DE69100282T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69100282T 1990-02-09 1991-01-23 Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. Expired - Fee Related DE69100282T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47809090A 1990-02-09 1990-02-09
PCT/US1991/000348 WO1991012003A1 (en) 1990-02-09 1991-01-23 Use of insulin sensitizing agents to treat hypertension

Publications (3)

Publication Number Publication Date
DE69100282D1 true DE69100282D1 (de) 1993-09-23
DE69100282T2 DE69100282T2 (de) 1994-01-05
DE69100282T3 DE69100282T3 (de) 2001-01-11

Family

ID=23898474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69100282T Expired - Fee Related DE69100282T3 (de) 1990-02-09 1991-01-23 Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.

Country Status (12)

Country Link
EP (1) EP0514452B2 (de)
JP (1) JP3544659B2 (de)
KR (1) KR0170416B1 (de)
AT (1) ATE93138T1 (de)
AU (1) AU651571B2 (de)
CA (1) CA2071629C (de)
DE (1) DE69100282T3 (de)
DK (1) DK0514452T4 (de)
ES (1) ES2059121T5 (de)
GR (1) GR3034508T3 (de)
HK (1) HK153996A (de)
WO (1) WO1991012003A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175179A (en) * 1991-09-25 1992-12-29 Pfizer Inc. Method for treating hypertension
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
SK283348B6 (sk) * 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
WO1997040017A2 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
KR20000016074A (ko) * 1996-05-31 2000-03-25 가와무라 요시부미 자기면역질환 치료제
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6313113B1 (en) * 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
WO1999024429A1 (fr) * 1997-11-12 1999-05-20 Kyoto Pharmaceutical Industries, Ltd. Nouveaux composes thiazolidine et utilisation de ceux-ci en medecine
EP1128845A1 (de) * 1998-11-11 2001-09-05 Smithkline Beecham Plc Kombinationen enthaltend einen beta-agonist und weiter antidiabetische substanzen
PE20010580A1 (es) * 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
EP2638898A1 (de) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Metformin- und Pioglitazonformulierung mit verschiedenen Freisetzungsprofilen
EP3025707A1 (de) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. Mehrschichtige tablette mit metformin und pioglitazon
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542927A (en) * 1965-08-10 1970-11-24 Pfizer Reduction of blood sugar levels with aminomethylindoles
EP0006735B1 (de) * 1978-06-28 1983-06-15 Beecham Group Plc Sekundäre Amine, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung
JPS5522636A (en) † 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
EP0052963B1 (de) * 1980-11-20 1985-02-20 Beecham Group Plc Sekundäre Amine
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3466387D1 (en) † 1983-11-04 1987-10-29 Beecham Group Plc Tertiary amines
US4602044A (en) † 1983-12-19 1986-07-22 Eli Lilly And Company β-phenethanolamine antiobesity agents
DE3419935A1 (de) * 1984-05-28 1985-11-28 Merck Patent Gmbh, 6100 Darmstadt Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
AR240698A1 (es) † 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
GB8607312D0 (en) † 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use

Also Published As

Publication number Publication date
AU651571B2 (en) 1994-07-28
CA2071629C (en) 1997-12-30
DK0514452T3 (da) 1993-11-29
AU7241691A (en) 1991-09-03
GR3034508T3 (en) 2000-12-29
ES2059121T5 (es) 2000-12-01
KR0170416B1 (ko) 1999-02-18
EP0514452B1 (de) 1993-08-18
CA2071629A1 (en) 1991-08-10
ES2059121T3 (es) 1994-11-01
ATE93138T1 (de) 1993-09-15
EP0514452B2 (de) 2000-07-19
DE69100282T3 (de) 2001-01-11
WO1991012003A1 (en) 1991-08-22
EP0514452A1 (de) 1992-11-25
JP3544659B2 (ja) 2004-07-21
DK0514452T4 (da) 2000-09-18
HK153996A (en) 1996-08-16
JPH05506430A (ja) 1993-09-22
DE69100282T2 (de) 1994-01-05

Similar Documents

Publication Publication Date Title
DE69100282D1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
CY1119109T1 (el) Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων
DE122007000002I2 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69424537D1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
HUP9700368A2 (hu) II-típusú diabetes mellitus kezelése amilin agonistákkal
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
ATE124258T1 (de) Schilddrüsenhormone zur kardialen behandlung.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE3770766D1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
DK0468258T3 (da) Substituerede pyridooxaziner
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
NO981719L (no) Anvendelse av protein S-100b i medisiner og medisiner inneholdende protein S-100b
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
SE9101341D0 (sv) New medicinal use
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
ATE328597T1 (de) Arzneimittel zur verminderung der effekte während oder nach der menopause und verfahren tur behandlung under verwendung derselben

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN CO., KALAMAZOO, MICH., US

8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee